转化医学杂志2024，Vol.13Issue(7)：1136-1140,5.DOI:10.3969/j.issn.2095-3097.2024.07.030
异烟肼联合莫西沙星对耐药性肺结核患者临床疗效及炎症因子的影响
The Clinical Efficacy of Isoniazid Combined with Moxifloxacin in Drug-Re-sistant Pulmonary Tuberculosis Patients and Its Impact on Inflammatory Factors
摘要
Abstract
Objective This study aims to evaluate the clinical efficacy of isoniazid combined with moxifloxacin in the treatment of drug-resistant pulmonary tuberculosis patients and its effects on inflammatory factors.Methods A retrospective analysis was conducted on the medical records of 120 drug-resistant pulmonary tuberculosis patients treated at Cangzhou Third Hospital from January 2022 to January 2024.The patients were divided into two groups:a control group(58 cases)and an observation group(62 cases).The control group was treated with isoniazid,while the observation group received a combina-tion therapy of isoniazid and moxifloxacin.Clinical efficacy,pulmonary lesion recovery,levels of inflammatory factors,and changes in immune cell levels were compared between the two groups.Results The treatment effectiveness rate in the obser-vation group was 95.16%,significantly higher than the 82.76%in the control group(P＜0.05).Furthermore,the sputum conversion rate,lesion absorption rate,and cavity closure rate in the observation group were significantly higher than those in the control group(P＜0.05).After treatment,the levels of TNF-α,CRP,and PCT in the observation group were significant-ly lower than in the control group(P＜0.05),while CD4+levels were higher and CD8+levels were lower in the observation group compared to the control group(P＜0.05).The incidence of adverse reactions showed no significant difference between the two groups(P＞0.05).Conclusion Isoniazid combined with moxifloxacin provides excellent therapeutic efficacy in the treatment of drug-resistant pulmonary tuberculosis,effectively reducing inflammatory response,with a high safety profile.关键词
耐药性肺结核/异烟肼/莫西沙星/炎症因子/临床疗效Key words
Drug-resistant pulmonary tuberculosis/Isoniazid/Moxifloxacin/Inflammatory factors/Clinical efficacy分类
医药卫生引用本文复制引用
李继翰,国美峰,倪磊磊,张新园,王桂芹,荣立萍..异烟肼联合莫西沙星对耐药性肺结核患者临床疗效及炎症因子的影响[J].转化医学杂志,2024,13(7):1136-1140,5.基金项目
2023年度河北省中医药管理局中医药类科学研究课题计划项目(2023272) （2023272）
